Last updated: February 20, 2026
What is NDC 70677-1156?
NDC 70677-1156 refers to a specific medication listed in the National Drug Code database. The drug is identified as Rituximab (brand name Rituxan), a monoclonal antibody used primarily to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Size and Demand Dynamics
Global Oncology and Autoimmune Markets
- The global oncology drug market was valued at $165 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7% through 2030 [1].
- The autoimmune therapeutics segment, which includes rituximab, was valued at $40 billion in 2022, with an expected CAGR of 8% over the next decade [2].
Rituximab-Specific Market
- Rituximab accounts for approximately 15% of the monoclonal antibody market in oncology and autoimmune indications.
- The drug is approved in over 70 countries, with significant sales in the U.S., Europe, and parts of Asia.
- Annual U.S. sales for rituximab products reached $3.5 billion in 2022 [3].
Competitive Landscape
- Key competitors include biosimilars such as Pfizer’s Truxima, Dr. Reddy’s Ruxience, and Celltrion’s Truxima.
- Biosimilar penetration in the U.S. reached 55% of rituximab prescriptions in 2022, up from 35% in 2020 [4].
Price Trends and Projections
Current Pricing
- The wholesale acquisition cost (WAC) for the originator product (Rituxan) is approximately $4,700 per 500 mg vial.
- Biosimilar versions are priced around $3,000 to $3,500 per vial, representing a 25-35% reduction from the originator.
Price Drivers
- Increased biosimilar adoption reduces the price of rituximab products.
- Payer pressure and patent expirations contribute to lower profit margins.
- Innovation in delivery methods or new indications may temporarily stabilize or increase prices.
Projected Price Trajectory (2023–2030)
| Year |
Originator Price (per 500 mg vial) |
Biosimilar Price (per 500 mg vial) |
Market Share of Biosimilars |
Notes |
| 2023 |
$4,700 |
$3,200 |
55% |
Biosimilar uptake accelerates |
| 2025 |
$4,800 |
$2,800 |
70% |
Increased biosimilar market share |
| 2027 |
$4,900 |
$2,500 |
80% |
Price stabilization with volume gains |
| 2030 |
$5,000 |
$2,200 |
90% |
Biosimilars dominate sales |
Key Factors Impacting Pricing
- Patent expiry of originator (patent expiration expected post-2023)
- Regulatory approval and uptake of biosimilars
- Payer negotiation and formulary decisions
- Manufacturer strategies to maintain margins
Regulatory and Market Access Landscape
U.S. Regulatory Context
- The FDA approved biosimilars for rituximab starting in 2017, with multiple approvals between 2017 and 2022.
- The biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA) allows for approval of interchangeable versions, influencing pricing and market share.
Reimbursement Policies
- CMS and private payers increasingly favor biosimilars for cost savings.
- Medicare covers biosimilars at levels comparable to originator products, incentivizing adoption.
Global Trends
- Europe has broader biosimilar adoption, with prices lower than in the U.S.
- Emerging markets show slower adoption but are catching up due to biosimilar affordability.
Conclusions
The market for NDC 70677-1156 (rituximab) is transitioning toward biosimilar dominance. Price reductions are likely to continue through 2030, driven by patent expirations and increased biosimilar penetration. Current prices suggest a downward trend, with the originator’s market share diminishing over time.
Key Takeaways
- The rituximab market is sizable, with global sales near $3.5 billion in the U.S. alone.
- Biosimilars are rapidly gaining market share, leading to a 25-35% price decrease from originator levels.
- Price projections indicate continued decline, with biosimilar prices potentially falling below $2,200 per vial by 2030.
- Regulatory frameworks and payer policies heavily influence future market dynamics.
- Consideration of biosimilar pipeline developments and patent expirations is vital for strategic planning.
FAQs
1. When does patent expiration occur for the original rituximab product?
Patents for Rituxan are expected to expire in the U.S. in 2023, facilitating biosimilar entry.
2. How significant is biosimilar adoption for market prices?
Biosimilar adoption reduces prices by approximately 25-35%, significantly shifting market share away from the originator.
3. What is the potential impact of new indications on prices?
Approved new indications could temporarily support higher prices or increase demand but are unlikely to offset biosimilar price pressures in the long term.
4. Are there biosimilar versions approved outside the U.S.?
Yes, biosimilars have been approved in Europe and other regions since 2017, with global market penetration increasing.
5. How do payer policies influence future prices?
Payers seek lower-cost options, favoring biosimilars, which accelerates price reductions and reduces profit margins for originators.
References
[1] Grand View Research. (2023). Oncology Drugs Market Size, Share & Trends. Retrieved from https://www.grandviewresearch.com/industry-analysis/oncology-drugs-market
[2] MarketWatch. (2022). Autoimmune Therapeutics Market. Retrieved from https://www.marketwatch.com/
[3] IQVIA. (2022). Prescription Data for Rituximab. Retrieved from https://www.iqvia.com/
[4] Evaluate Pharma. (2022). Biosimilar Market Penetration. Retrieved from https://www.evaluate.com/
